Accessibility Menu
Galera Therapeutics logo

Galera Therapeutics

(OTC) GRTX

Current Price$0.10
Market Cap$15.25M
Since IPO (2019)-99%
5 Year-99%
1 Year+301%
1 Month-5%

Galera Therapeutics Financials at a Glance

Market Cap

$15.25M

Revenue (TTM)

$0.00

Net Income (TTM)

$149.04M

EPS (TTM)

$1.98

P/E Ratio

0.05

Dividend

$0.00

Beta (Volatility)

0.49 (Low)

Price

$0.10

Volume

160,154

Open

$0.10

Previous Close

$0.10

Daily Range

$0.09 - $0.10

52-Week Range

$0.02 - $0.15

Estimated Earnings Date

Aug 12, 2026

GRTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Galera Therapeutics

Industry

Biotechnology

Employees

3

CEO

John Mel Sorensen, MD

Headquarters

Malvern, PA 19355, US

GRTX Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

0%

Return on Capital

-1%

Return on Assets

24%

Earnings Yield

20.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$15.25M

Shares Outstanding

160.55M

Volume

160.15K

Avg. Volume

297.25K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$6.04M

EBITDA

-$6.04M

Operating Cash Flow

-$6.05M

Capital Expenditure

$0.00

Free Cash Flow

-$6.05M

Cash & ST Invst.

$6.38M

Total Debt

$0.00

Galera Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$15.25M

N/A

Market Cap/Employee

$5.08M

N/A

Employees

3

N/A

Net Income

-$1.61M

-0.9%

EBITDA

-$1.66M

+15.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

$5.50M

-17.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

24.18%

N/A

Return on Invested Capital

-1.14%

N/A

Free Cash Flow

-$2.24M

+4.3%

Operating Cash Flow

-$2.24M

+4.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VCNXVaccinex, Inc.
$1.00+29.87%
HESGHealth Sciences Group, Inc.
$0.00+0.00%
NBCONeon Bloom, Inc.
$0.01+0.00%
HEMPHemp, Inc
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$14.38-0.13%
TQQQProShares Trust - ProShares UltraPro Qqq
$73.05-0.14%
KEELKeel Infrastructure
$5.13-0.13%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.19+0.14%

Questions About GRTX

What is the current price of Galera Therapeutics?

Galera Therapeutics is trading at $0.10 per share.

What is the 52-week range for Galera Therapeutics?

Over the past 52 weeks, Galera Therapeutics has traded between $0.02 and $0.15.

How much debt does Galera Therapeutics have?

As of the most recent reporting period, Galera Therapeutics reported total debt of $0.00.

How much cash does Galera Therapeutics have on hand?

Galera Therapeutics reported $5.50M in cash and cash equivalents in its most recent financial results.

What is Galera Therapeutics’s dividend yield?

Galera Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.